Highlights

  • Pro Medicus reported FY26 Revenue of AUD 261.7 million, up 22.9%.
  • Underlying net profit after tax increased 24.1% to AUD 144.7 million.
  • Ten new contracts carried a minimum combined value of AUD 407 million.
  • Six renewals covered AUD 141 million of contracted value.

Medical imaging software provider Pro Medicus (ASX:PME) reported revenue growth in the year ended 30 June 2026, with the operating story extending beyond the headline profit figure. Revenue increased 22.9% to AUD 261.7 million, supported by Demand for its Visage imaging products. In results released on 18 August, the company reported ten new contracts with minimum total value of AUD 407 million and six contract renewals worth AUD 141 million. Contract values are not immediately recognised as revenue.

Revenue, Earnings and the Non-Cash Distinction

Underlying earnings before interest and tax reached AUD 196.1 million, a rise of 24.4%, while underlying net profit after tax increased 24.1% to AUD 144.7 million. The underlying EBIT Margin advanced 90 basis points to 74.9%. The combination of revenue expansion and margin improvement indicates that revenue growth was not fully absorbed by operating expenses.

Reported net profit after tax was AUD 265.3 million, up 130.3%, but differed substantially from the underlying measure. The Annual Report identifies unrealised fair-value gains relating to investments, including 4DMedical and EchoIQ, as an important Factor in the reported figure. Separating operating profit from these valuation movements provides a clearer perspective on performance generated through healthcare imaging services.

Ten Contracts Extend the Implementation Pipeline

New agreements during FY26 included a ten-year, AUD 170 million contract with UCHealth Colorado for a full-stack imaging and cardiology solution and a seven-year, AUD 90 million contract with Beth Israel Lahey Health. The company secured nine contracts in North America and one with the University of Heidelberg in Europe. Contract durations, deployment schedules and usage-based components affect the timing at which commercial value enters revenue.

Pro Medicus also renewed all six contracts scheduled for renewal, representing AUD 141 million across five-year terms. This renewal outcome is distinct from new wins: it indicates continued customer engagement with the installed platform. The company reported sixteen completed implementations, connecting signed contracts to actual service deployment, an operational step necessary before various Recurring Revenue streams can develop.

Visage Concentration and Product Expansion

The annual report attributed AUD 244.6 million of FY26 revenue to the Visage 7 and Open Archive picture archiving and communication systems, compared with AUD 197.0 million a year earlier. North America generated AUD 236.8 million of total revenue, making it the dominant geographic market. That scale supports the earnings profile but creates sensitivity to US hospital spending, implementation scheduling and competition for major health-network contracts.

Cash Resources and Execution Risks

Cash and other financial Assets totalled AUD 252.3 million at year-end, up 19.7%, and management reported that the group remained debt-free. The financial position offers capacity to support product Investment and major implementations, without eliminating operational risks from complex customer deployments.

Revenue measured on a constant-currency basis grew 28.4% to AUD 273.5 million, faster than reported revenue, illustrating how foreign exchange affected translation. Future disclosures can be assessed through contract implementation, client renewal, product uptake and the distinction between recurring operating performance and investment valuation changes.

Key Insights

Pro Medicus’s FY26 story brings together AUD 261.7 million of revenue, Underlying Profit growth and a AUD 407 million new-contract intake. Six renewals and sixteen completed implementations provide operational context for the contract pipeline. Its dominant North American imaging Business remains the main earnings engine, while foreign exchange, implementation timing and non-cash investment movements complicate comparisons of reported profit.